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Wiskott–Aldrich syndrome (WAS) is an X-linked disorder characterized by eczema, thrombocytopenia and increased susceptibility of
infections, with mutations of theWAS gene being responsible for WAS and X-linked thrombocytopenia. Herein, two novel mutations of WAS
at T336C on exon 3, and at 1326–1329, a G deletion on exon 10, resulting in L101P missense mutation and frameshift mutation 444 stop,
respectively, are reported. The affected patients with either mutation showed severe suppression of WAS protein (WASP) levels, T cell
proliferation, and CFSE-labeled T cells division. Because WASP L101 have not shown direct nuclear Overhauser effect (NOE) contact with
the WASP-interacting protein (WIP) in NMR spectroscopy, molecular modeling was performed to evaluate the molecular effect of WASP
P101 to WIP peptide. It is presumed that P101 induced a conformational change in the Q99 residue of WASP and made the side chain of Q99
move away from the WIP peptide, resulting in disruption of the hydrogen bond between Q99 WASP and Y475 WIP. A possible model for the
molecular pathogenesis of WAS has been proposed by analyzing the interactions of WASP and WIP using a molecular modeling study.
D 2004 Elsevier B.V. All rights reserved.Keywords: Wiskott–Aldrich syndrome (WAS); WAS protein (WASP); WASP-interacting protein (WIP); Molecular modeling
1. Introduction transduction protein that is expressed in hematopoieticWiskott–Aldrich syndrome (WAS) is an X-linked disor-
der characterized by eczema, thrombocytopenia and immu-
nodeficiency [1,2]. Classical WAS is often associated with
the absence of WAS protein (WASP) caused by mutations in
the WAS gene [3], which consists of 12 exons located on the
X-chromosome at Xp11.22–p11.23 [4]. WASP is a signal0925-4439/$ - see front matter D 2004 Elsevier B.V. All rights reserved.
doi:10.1016/j.bbadis.2004.06.007
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merization [5] and has a possible role in motility [6],
phagocytosis [7] and activation of T [8] and B cells [9].
WAS gene encodes a 502-amino-acid protein which
consists of a WASP homology 1 (WH1) domain, basic
region (BR), GTPase-binding domain (GBD), polyproline
(PP) domain, verprolin-cofilin homology (V/C, or WH2)
domain, and a carboxy-terminal acidic (A) domain [1,2].
WASP can bind to a variety of proteins [1,2]; the WH1
domain at the N-terminal region of WASP interacts with
the WASP-interacting protein (WIP) [10,11], which is
important for NF-AT/AP-1-mediated gene transcription
by cooperating with Vav [12]; for actin-tail formation
[11], BR and GBD interact with GTP-bound Cdc42,
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several signaling and adaptor molecules, such as Nck,
Grb2, Fyn, CrkL, Bruton’s tyrosine kinase (Btk) and
proline-serine-threonine phosphatase-interacting protein
(PSTPIP). The V/C and A domains of WASP also recruit
actin-related protein (Arp) 2/3 complex for actin polymer-
ization [1,13].
Recently, NMR spectroscopy and computer modeling
studies to WASP WH1 and N-WASP EVH1, which are
highly homologous WASP WH1 domains, have been able to
predict the structure of WASP WH1 and its molecular
interaction with WIP peptide [14,15]. The pathogenesis of
WAS could be understood in detail by analyzing the
missense mutation events of WASP WH1 through the
structural basis of WASP WH1 to WIP.
In the present study, two novel mutations of WAS gene, a
missense mutation of L101P WASP on exon 3 (family A;
patient 1 and 2) and a deletion frameshift on exon 10 (family
B; patient 3), both of which caused defects in CFSE-stained
T cell division, are reported. We here analyzed the molecular
interaction of the mutated P101 WASP with WIP peptide
using molecular modeling because L101 WASP was not the
direct binding site to WIP in the NMR spectroscopy [14]
and the WASP expression was only decreased but not
absent. P101 WASP was found to make the side chain of
Q99 WASP move away from the WIP peptide and disrupt
the hydrogen bond between Q99 of WASP and Y475 of
WIP.Fig. 1. Analysis of WASP expression. Pedigrees of families A and B with WAS
patients 1 and 2 (B left) and of patient 3 (B right) are shown. Each brother of pat
PBMCs were derived from patients (Pt) 1 and 3, normal controls (Cont) 1 and 3. M
used as control cells. (For color see online version).2. Patients, materials and methods
2.1. Patients
2.1.1. Family A
Patient 1 (the index case), a 29-year-old man, had chronic
idiopathic thrombocytopenia diagnosed at 7 years of age
(Fig. 1A). He had a splenectomy for the treatment of
idiopathic thrombocytopenic purpura (ITP), and was admit-
ted due to pneumonia, meningoencephalitis and bacterial
meningitis. Streptococcus pneumoniae type 6A was identi-
fied in a blood culture and Acinetobacter baumanii and
vancomycin-resistant enterococci were identified in his
sputum. His platelet count and MPV were 30 109/l and
8.5 fL, respectively. Platelet aggregation tests showed de-
pressed responses to ADP, collagen, epinephrine and risto-
cetin. No secondary response wave was observed, revealing
a pattern of storage pool deficiency. The immune cells
were 41% of CD4+ T cells, 23.6% of CD8+ T cells, and
11.2% of B cells. The serum IgG, IgA and IgM levels were
normal. His clinical score [16] was 4 and he died of
intracerebral hemorrhage during the treatment. His brother,
who suffered with ITP, died at an early age due to suspicious
infections. His nephew (patient 2), a 4-year-old boy, was
admitted due to recurrent intussusception. The platelet count
was 30 109/l and the clinical score was 3. The nephew’s
brother was also diagnosed with ITP and died at 8 years
of age.patients (A) and their genomic DNA analyses for the WASP mutations of
ients 1 and 2 died at an early age. (C) The Western blot analysis of WASP.
olt-4, a T cell line which expressed barely or not detectable WASP [36], was
Fig. 2. T cell proliferation. (A) PBMCs (1105 cells/well) were incubated
with PHA at concentrations of 1 or 10 Ag/ml for 72 h, and the cells labeled
with [3H]-thymidine for a further 18 h. The thymidine incorporation was
measured and themean cpm values used for the analysis. The black andwhite
circles and squares represent the patients and age-matched normal controls,
respectively. (B) In vitro tracking of live CD3+ T cells. CFSE-labeled
PBMCs (Pts 1 and 3, and Cont 1 and 3) were cultured with 1 Ag/ml PHA for
90 h, the cells harvested and then stained with PE-conjugated anti-CD3. The
cells were stained with propidium iodide and the live CD3+ T cells analyzed
by flow cytometry. The arrow indicates the number of cell divisions.
iophy2.1.2. Family B
Patient 3 was an 18-month-old boy of non-consanguin-
eous parents. He had eczema, intermittent petechiae with
bruising and a clinical score of 4. The platelet count and
MPV were 14.7 109/l and 7.7 fL of the low-normal
limit, respectively. The serum IgG, IgA and IgM levels
were normal, but the IgE level was highly elevated to
2310 IU/ml (normal range; < 17 IU/ml). He had a
congenital cytomegalovirus (CMV) infection confirmed
by positive anti-CMV IgM in the serum and CMV
DNA PCR of urine samples, but no chorioretinitis or
hearing loss was observed. The immune cells were 11.7%
of CD4+ T cells, 28.5% of CD8+ T cells, 3.3% of NK
cells, and 53.8% of B cells. HIV RNA was not detected
in the serum sample by PCR. His bone marrow finding of
myeloid to erythroid cells was increased, with fully
matured myeloid cells, abundant number of megakaryo-
cytes and marked lymphocytosis.
2.2. Mutation analysis at the WAS gene
Genomic DNA was extracted from peripheral blood and
the 12 exons, containing flanking splice sites at the WAS
locus, were amplified as described [17]. DNA sequencing
was performed in both directions using an ABI Prism 310
sequencer (Applied Biosystem, Foster City, CA, USA).
2.3. Analysis of WASP expression
Peripheral blood mononuclear cells (PBMCs) were iso-
lated by Ficoll-hypaque gradients. The cells were lysed
using 1% Nonidet P-40 buffer, containing a protease inhib-
itor cocktail (Sigma), and the concentrations of cytoplasmic
protein measured by the Bradford assay (Biorad). After
normalization of the concentrations of cytoplasmic protein,
the protein lysates underwent 10% sodium dodecyl sulfate-
polyacrylamide gel electrophoresis, and were transferred to
a nitrocellulose membrane. Western blot analysis was per-
formed using the monoclonal anti-WASP to amino acids 1–
250 of WASP of human origin (Santa Cruz Biotechnology,
Santa Cruz, CA, USA) with HRP-labeled rabbit anti-mouse
Ig used as a secondary antibody. The signal was revealed
with enhanced chemiluminescence (Pierce, Rockford, IL,
USA).
2.4. Proliferation assay
PBMCs, in 10% FBS-RPMI1640 (Gibco), containing 2
mM L-glutamine, 100 Ag/ml streptomycin and 100 U/ml
penicillin, were plated at 1105 cells/well in 96-well U-
bottom plates. Phytohemagglutinin (PHA) was added to the
wells at the concentrations of 1 or 10 Ag/ml and incubated
for 72 h. The cells were labeled with [3H]-thymidine for 18
h. Thymidine incorporation was measured in triplicates by
liquid scintillation counting, with the mean values used for
the analysis.
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The PBMCs were labeled with 5 AM CFSE dye (Mo-
lecular Probes, Eugene, OR, USA) for 10 min at 37 jC [18],
washed three times with 0.1% BSA-PBS and cultured with
PHA at 1 Ag/ml for 90 h. The cells were washed and
incubated with PE-conjugated anti-CD3 (BD Biosciences,
San Jose, CA, USA) at 4 jC for 30 min. The cells were
incubated with propidium iodide to exclude dead cells, and
then analyzed by flow cytometry (Beckman Coulter, Miami,
FL, USA).
2.6. Molecular modeling
Primary sequences of human WASP and WIP were
retrieved from Swiss-Prot [19]. In order to search the
template for homology modeling, PSI-BLAST was carried
out with the WASP and WIP sequences against the Protein
Data Bank (PDB, http://www.rcsb.org/pdb) [20]. The ho-
mology modeling was performed using the InsightII2000
sica Acta 1690 (2004) 134–140
Fig. 3. Molecular modeling of WASP L101P with WIP peptide. (A) Sequence alignment of human WASP with the PDB code of 1 mke. Identities are shown
with the (:) symbol, and similarities (or conservative replacements) with the (.) symbol. The arrow is the mutation site of WASP L101. (B-1) The model
structure of the human WASP–WIP peptide complex. Purple, human WASP (residues R34–R148); cyan, WIP peptide (residues D461–P476); green, residue
L101; red, residues Q99, E100, Y102 and S103. Molecular modeling of L101 wild (B-2) and P101 mutant (B-3) WASP with WIP peptide. The hydrogen bond
between Q99 in wild WASP and Y475 in WIP is shown by the green line (B-2) and the distances (white dotted line) between the side chain nitrogen of Q99 and
the side chain oxygen of Y475 were 3.01 and 5.39 A˚ in wild WASP and L101P mutant, respectively. Blue, nitrogen; red, oxygen; green, carbon.
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was constructed by replacement of the corresponding resi-
due. To refine the model structures, each structure was
energy-minimized using the steepest descents for 500 steps
and conjugate gradients for 5000 steps with a distance-
dependent dielectric constant (4*r). All molecular mechan-
ics calculations were carried out using the Discover2.98
program (Accelrys) with AMBER force field using a
nonbonded cutoff of 12 A˚ running on a Silicon Graphics
O2 workstation.3. Results
Patients 1 and 2 showed T336C nucleotide substitution
on exon 3 of the WAS gene, resulting in L101P missense
mutations (Fig. 1A and B). Heterozygosity for this mutation
was detected in three sisters, the mother and one niece of
patient 1. Patient 3 showed a G deletion on 1326–1329 of
exon 10, resulting in a frameshift mutation that eventually
stop at amino acid 444 (Fig. 1A and B). Both mutations
were novel findings, with all three patients in this study
having classical WAS phenotypes. The expression of WASP
in unstimulated PBMCs was severely suppressed to 42% of
control 1 in patient 1 and undetected in patient 3 (Fig. 1C).
The in vitro lymphocyte proliferation to 1 Ag/ml PHA
was markedly decreased to 5–15% (patient 1) and 2–10%
(patient 3) of those of the age-matched normal controls, and
low proliferative responses, even at high concentration of 10
Ag/ml PHA (Fig. 2A). To investigate the cell division
processing of T cells, PBMCs labeled with CFSE dye were
cultured with 1 Ag/ml of PHA for 90 h and then the cells
stained with anti-CD3 Ab and propidium iodide. The
numbers of live CD3+ T cell division generations were
severely decreased two to three times in patients 1 and 3
with both mutations, compared to the six to seven times of
the age-matched normal controls (Fig. 2B). The numbers of
mitotic events of the live T cells, from a total of 20,000
CD3+ T cells gated, were 944 (patient 1), 627 (patient 3),
6061 (control 1) and 12,437 (control 3), and the percentages
for patients 1 and 3 were 15.6% and 5.0% of the normal
controls, respectively (data not shown). The percentages of
live CD3+ T cells among the total CD3+ T cells after
polyclonal activation were only 11.6% and 8.1% (Pt 1 and
3, respectively), compared to the 44.4% and 52.5% (Cont 1
and 3, respectively) (data not shown), indicating suscepti-
bility of T cell deaths after T cell activation.
The L101 of WASP was identified as a highly conserved
hydrophobic amino acid in multiple sequence alignment of
the WH1 domains of the WASPs from several different
species [15]. However, it did not show direct NOE contact
with the WIP peptide, although the neighboring amino acids
of Q99, E100, Y102 and S103 showed interactions with the
WIP peptide on NMR spectroscopy [14]. How the novel
L101P WASP missense mutation influences the interaction
with the WIP peptide was analyzed using molecular mod-eling, based on the NMR structure of the N-WASP EVH1
(pdb code of 1 mke)–WIP complex [14]. The sequence
alignment of human WASP with 1 mke (sequence identity
of 47.5%) was obtained from a PSI-BLAST search (Fig.
3A). This alignment suggested that 1 mke could be a good
template for homology modeling [21,22]. The human
WASP–WIP peptide complex structure was built by ho-
mology modeling using 1 mke as a template (Fig. 3A).
WASP WH1 from R34 to R148 and WIP peptide from
D461 to P476 were used for the modeling. It seems that the
L101P WASP mutation has no effect on the WASP–WIP
interactions, as it does not contact with the WIP [14].
According to our data, the model structure of the human
WASP–WIP complex showed that the amino acid residues
(Q99, E100, Y102, and S103) around L101 have interac-
tions with WIP, but not L101 (Fig. 3B-1). In order to
investigate the effect of the L101P mutation, molecular
modeling studies were carried out on wild and L101P
mutant WASP. The models achieved from the molecular
modeling suggest that the L101P mutation makes the side
chain of Q99 move away from the WIP peptide and disrupts
the hydrogen bond between Q99 of WASP and Y475 of
WIP (Fig. 3B-3), although the wild WASP maintained the
hydrogen bond (Fig. 3B-2). The distances between the side
chain nitrogen of Q99 of WASP and the side chain oxygen
of Y475 of WIP peptide are 3.01 and 5.39 A˚ in wild WASP
and L101P mutant, respectively (Fig. 3B-2 and B-3).4. Discussion
Herein, two novel mutations of L101P WASP missense
and frameshift mutation of WASP 444 stop, respectively, are
reported. The WASP 444 stop, by a G deletion in 1326–
1329, which deleted a partial region of the V/C and the
whole A domain of WASP, is predicted to interfere the
Arp2/3-mediated actin polymerization [1,13]. This effect is
similar to that seen with 1030–1035 del G, 1109–1113 del
C or 1301–1305 del G, each of which has a stop codon at
the 444th residue [23,24].
In the case of the L101Pmissense mutation ofWASP, how
the P101WASP influences the interaction was predicted with
WIP at the molecular level, although the L101 WASP is
found not to be the site of the NOE with the WIP peptide in
the NMR spectroscopy study [14]. WASP expressions in
PBMCs is correlated with that of T cells [25], and it is
necessary to analyze the interaction of WASP and WIP,
specifically, how residual L101P WASP in T cells disrupts
the interaction with WIP. And the observation of T cell
proliferation defect and impaired IL-2 production by anti-
CD3 stimulation inWIP-deficient mice suggested thatWIP is
important for T cell activation [26]. Considering that human
WIP residues 461–485 wrap around the N-WASP EVH1
domain amino acids 26–147, a highly homologous protein to
the human WASP WH1 domain [14], the L101P missense
mutation induces WAS by weakening the interactions be-
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direct interaction with WIP. Therefore, it is suggested that the
hydrogen bond between Q99WASP and Y475WIP is one of
important interactions, and its breakage by the mutation at
Q99, or the neighboring amino acid which influences its side
chain, can disrupt the WASP–WIP interaction. We observed
that the Q99R WASP mutation [27] weakened the WASP–
WIP interactions in our modeling study (data not shown). In
the study of the WASP–WIP interaction using the yeast two-
hybrid system and in vitro WASP–WIP binding assay
[28,29], WASP missense mutants such as R86H, Y107C,
A134T, and R138P impaired the interaction with WIP in
quantitative level, suggesting that the configuration is neces-
sary for the interaction. For the future work in our study, the
functional studies such as co-transfection or co-immunopre-
cipitation in cells will be helpful to show the consequences of
L101P mutation with WIP.
The genotype–phenotype correlation in WAS/XLT was
reported independently by several investigators, and is still
controversial. Greer et al. [27] and Schindelhauer et al. [17]
suggested no strict correlations. In contrast, Zhu et al. [23]
showed that missense mutations in exons 1–3 caused mild
disease permitting WASP expression. Recently, Imai et al.
[30] analyzed the clinical phenotype and course of 50 WAS/
XLT patients longitudinally. They demonstrated that WASP-
positive WAS patients had better hematological and immu-
nological findings, such as bleeding tendency, episodes of
infection and severity of eczema, and also had a longer
survival time than WASP-negative patients. In L101P mis-
sense mutation, detectable WASP expression was shown but
the patient showed a clinically WAS phenotype. It is pre-
sumed that the low level of WASP expression and the
weakening of WASP–WIP interaction by the disruption of
hydrogen bondwere involved in the disease progression. And
there is a possibility of destruction of the binding between
WASP WH1 and unknown ligand to be considered.
T cells of the affected patients with either mutation had
dysfunctions of the continuous cell divisions, and T cell
viabilities were severely decreased after PHA stimulation. In
the study of the unselected 94 WAS patients, 66% of WAS
patients were reported to have normal PHA response al-
though 34% of the patients had decreased response [31],
indicating the heterogeneity of the PHA response. The
several reasons for defective T cell division and T cell
viability were probably due to the decreased IL-2 produc-
tion [32,33] or the increased apoptosis by Fas up-regulation
[34]. In the regulation of T cell activation, NF-AT/AP-1
gene transcription is important in mediating normal signals
from the T cell receptor, and Vav is a potent regulator of the
IL-2 promoter by regulating the activity of the NF-AT/AP-1
transcriptional factor complex [35]. Savoy et al. [12] dem-
onstrated that a functional WASP–WIP complex is required
to enhance Vav-mediated activation of NF-AT/AP-1 gene
transcription. So it would be helpful to observe the NF-AT/
AP-1 activity that is triggered upon WIP interaction with
WH1 domain of WASP.In conclusion, a possible model for the molecular path-
ogenesis of WAS was proposed first on the aspect of the
configuration change of the tertiary structure, as far as we
know, by analyzing the interactions of WASP and WIP
using a molecular modeling study.Acknowledgements
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